- Research article
- Open Access
- Open Peer Review
Analysis of tanshinone IIA induced cellular apoptosis in leukemia cells by genome-wide expression profiling
- Chang Liu†1Email author,
- Jianqin Li†1,
- Liangjie Wang†4,
- Fuqun Wu2,
- Linfang Huang1,
- Yue Xu2, 3,
- Jieyu Ye2,
- Bin Xiao2, 3,
- Fanyi Meng2,
- Shilin Chen1 and
- Mo Yang2, 4Email author
© Liu et al; licensee BioMed Central Ltd. 2012
- Received: 27 May 2011
- Accepted: 16 January 2012
- Published: 16 January 2012
Tanshinone IIA (Tan IIA) is a diterpene quinone extracted from the root of Salvia miltiorrhiza, a Chinese traditional herb. Although previous studies have reported the anti-tumor effects of Tan IIA on various human cancer cells, the underlying mechanisms are not clear. The current study was undertaken to investigate the molecular mechanisms of Tan IIA's apoptotic effects on leukemia cells in vitro.
The cytotoxicity of Tan IIA on different types of leukemia cell lines was evaluated by the 3-[4,5-dimethylthiazol-2,5]-diphenyl tetrazolium bromide (MTT) assay on cells treated without or with Tan IIA at different concentrations for different time periods. Cellular apoptosis progression with and without Tan IIA treatment was analyzed by Annexin V and Caspase 3 assays. Gene expression profiling was used to identify the genes regulated after Tan IIA treatment and those differentially expressed among the five cell lines. Confirmation of these expression regulations was carried out using real-time quantitative PCR and ELISA. The antagonizing effect of a PXR inhibitor L-SFN on Tan IIA treatment was tested using Colony Forming Unit Assay.
Our results revealed that Tan IIA had different cytotoxic activities on five types of leukemia cells, with the highest toxicity on U-937 cells. Tan IIA inhibited the growth of U-937 cells in a time- and dose-dependent manner. Annexin V and Caspase-3 assays showed that Tan IIA induced apoptosis in U-937 cells. Using gene expression profiling, 366 genes were found to be significantly regulated after Tan IIA treatment and differentially expressed among the five cell lines. Among these genes, CCL2 was highly expressed in untreated U-937 cells and down-regulated significantly after Tan IIA treatment in a dose-dependent manner. RT-qPCR analyses validated the expression regulation of 80% of genes. Addition of L- sulforaphane (L-SFN), an inhibitor of Pregnane × receptor (PXR) significantly attenuated Tan IIA's effects using colony forming assays.
Tan IIA has significant growth inhibition effects on U-937 cells through the induction of apoptosis. And Tan IIA-induced apoptosis might result from the activation of PXR, which suppresses the activity of NF-κB and lead to the down-regulation of CCL2 expression.
- Gene expression profiling
- U-937 cell lines
- tanshinone IIA (Tan IIA)
Leukemia is one of the common malignant diseases. Artificial ionizing radiation, viruses, benzene, some petro-chemicals, and alkylating chemotherapy agents are now recognized as major causes of leukemia . Approximately 80-100 million children and adults around the world develop some forms of leukemia each year. Identification of anti-leukemia therapies remains a top research priority. Recently, traditional Chinese herbal medicines have gained wide attention as alternative clinical options for the treatment of various malignant diseases, including leukemia, due to their antiviral, antioxidant, anti-inflammatory, and tumor apoptosis-inducing properties [2, 3]. We are interested in the characterization of chemical compounds from these herbal medicines for further development.
Tanshinone IIA (Tan IIA) is a diterpene quinone extracted from the root of Salvia miltiorrhiza Bunge. The growth-inhibitory and apoptosis-inducing effects of Tan IIA on leukemia cells have recently been reported. For example, Tan IIA induced apoptosis in human leukemia cell lines HL-60 and K562 through the activation of caspase-3 . Liu reported that the disruption of Δψm, activation of caspase-3, down-regulation of Bcl-2, survivin, and up-regulation of Bax were mainly responsible for Tan IIA-induced apoptosis on THP-1 cells . In acute promyelocytic leukemia cells NB4, Tan IIA could promote cell differentiation and apoptosis with elevated C/EBP β and CHOP .
Tan IIA toxicities on other cancer lines have also been reported. Tan IIA could inhibit the growth of human hepatocellular carcinoma cells SMMC-7211 by apoptosis induction as a result of the up-regulation of P53, Fas and Bax, and the down-regulation of c-Myc and Bcl-2 . Su suggested that the Tan IIA-induced apoptosis of breast cancer cells MDA-MB-231 may be attributed to the increased Bax to Bcl-xL expression ratios . Lu reported that Tan IIA induced apoptosis in human breast cancer lines MCF-7 and MDA-MB-231 by decreasing the expression of P53 and Bcl-2 . In HeLa cells, Tan IIA led cancer cells to G2/M phase arrest and subsequent apoptosis by disturbing the microtubule assembly [10, 11]. In lung cancer A549 cells, Tan IIA-induced apoptosis was associated with a higher ratio of Bax/Bcl-2 .
The above studies have proposed different mechanisms of Tan IIA-induced apoptosis. The inconsistency in these proposed mechanisms may have resulted from the genetic diversities among the cell systems under study and the fact that the above studies focused on particular sets of genes or aspects. In the current paper, instead of focusing on a few candidate genes, we employed genome-wide expression profiling to identify the genes that are differentially expressed among leukemia cell lines exhibiting various Tan IIA sensitivities and significantly regulated after Tan IIA treatment as a way to elucidate the molecular mechanisms of Tan IIA in a systematic manner.
Reagents and cell culture conditions
The cell lines used in the current study include HL-60 (Human promyelocytic leukemia), U-937 (Human leukemic monocyte lymphoma), THP-1 (Human acute monocytic leukemia), MEG-01 (megakaryoblastic leukemia) and MOLT-4 (Human acute lymphoblastic leukemia). They were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured according to the manufacturer's instructions. Tan IIA (National Institute for the Control of Pharmaceutical and Biological Products, P.R.China) was dissolved in DMSO solution (0.01%). The stock concentration of Tan IIA was 200 μg/mL. L-sulforaphane (L-SFN) was purchased from Sigma-Aldrich (Shanghai, China) Trading Co., Ltd.
Cytotoxicity assay for various cancer cell lines
Cell viability was evaluated by the 3-[4, 5-dimethylthiazol-2, 5]-diphenyl tetrazolium bromide (MTT) assay in triplicate . For the experiments comparing the five cell lines, each cell line (2.5 × 105 cells/well) was cultured in the recommended medium in 96-well plates for 24 h. The culture medium was then removed, and the cells were treated with 0.1% DMSO as vehicle control or Tan IIA at 30 μg/mL. At the end of the cultivation, 20 μl of MTT working solution was added to the wells, which were incubated for an additional 4 h at 37°C. Finally, the absorbance of each well was measured using a micro-titer plate reader (TECAN, Vienna, Austria) at 570 nm. For the dose- and time-dependent experiments, the U-937 cells were treated with Tan IIA at concentrations of 1, 2, 3, 5 and 10 μg/mL for 0, 12, 24, 36 and 48 h, respectively.
Detection of Tan IIA-induced apoptosis in U-937 cells using Annexin V and Caspase-3 assays
The assays were performed as described previously . Briefly, the U-937 cells were maintained in DMEM medium plus 10% fetal bovine serum. Tan IIA (3 μg/mL) was added and the cells were cultured for 12, 24, 36 and 48 h, respectively. The vehicle control groups were treated with 0.1% DMSO. Apoptotic cell death was examined using annexin V-FITC/PI and active caspase-3-PE reagent kits (BD Biosciences, San Diego, CA, USA) according to the manufacturer's instructions. Ten thousand events were acquired for each sample and analyzed by flow cytometry using Lysis II software (FACScan; BD Pharmingen).
To determine the expression levels of genome-wide gene transcripts in Tan IIA-treated and control cells, RNA was extracted using RNA extraction kit (Ambion, TX) according to manufacturer's instructions. Five μg of high-quality total RNA per sample was first converted to double-stranded cDNA. Biotin-labelled cRNA was subsequently synthesized on cDNA templates and fragmented prior to hybridization to Affymetrix GeneChip HG-U133 plus 2 slides following the manufacturer's recommendations (Affymetrix, Santa Clara, CA, USA). The integrity of cDNA, cRNA, and fragmented cRNA was assessed by running aliquots on the Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA). Hybridized probes were detected with streptavidin-phycoerythrin and scanned on an Affymetrix GeneChip Scanner 3000 (Affymetrix, Santa Clara, CA, USA).
Microarray data analysis
Microarray images were visually inspected for hybridization artifacts and then analyzed with Affymetrix GeneChip Operating Software (GCOS) according to Affymetrix's guidelines (http://www.affymetrix.com). Affymetrix Microarray Suite MAS 5.0 algorithm was used for intensity estimation and data normalization. The cell intensity files (.cel) of all arrays were also analyzed using dChip software , which employs the invariant set normalization method to normalize the arrays. In addition, the PM-only model was used to detect the less-abundant genes in a more sensitive fashion [16, 17]. Functional annotation of genes was performed at the NETAFFX Analysis Center. MAPPFinder  was used to find all pathway maps containing the significantly differentially expressed genes (SDEGs). The GeneChip data have been submitted to NCBI's Gene Expression Omnibus with accession number GSE33358.
Real-time quantitative Polymerase Chain Reaction (RT-qPCR)
U-937 cells were treated with Tan IIA at 3 μg/mL and cultured for 1, 2, 4, 6, 12, 24 and 36 h. Total cellular RNA was extracted using Trizol reagent (Invitrogen Corp., Carlsbad, CA, USA). The cDNAs were synthesized using M-MLV reverse transcriptase with oligo-d (T) 15 primers according to the manufacturer's instructions (Promega, Madison, WI, USA). The primers used to detect the expression of target genes are listed in Additional file 1, Table S1. ABL was used as internal control. RT-qPCR was performed with SYBR-Green I intercalating dye (Bio-Rad, Hercules, CA, USA) using a MyiQ Single Color Real-time PCR Detection System (Bio-Rad). The following PCR program was used: an initial denaturation at 95°C for 5 min, 40 cycles of 95°C for 15 s, 60°C for 15 s and 72°C for 20 s. The RT-qPCR data were analyzed using the MyiQ software (Bio-Rad). All experiments were independently repeated three times.
Enzyme-linked immunosorbent assay (ELISA)
U-937 cells were treated with Tan IIA at different concentrations of 0, 1, 3, 6 and 18 μg/mL for 12 h and harvested for ELISA. The expression level of CCL2 was determined using an ELISA kit (R & D, Minneapolis, MN, USA) following the manufacturer's instructions. A monoclonal antibody specific for CCL2 was pre-coated onto a microplate. Standards and samples were added to the wells. After washing away the unbound substances, enzyme-linked polyclonal antibodies specific for CCL2 were added to the wells. Subsequently, substrates were added. The colors developed were in proportion to the amount of CCL2 bound on the wells. The optical density of each well was measured using a microreader (DNATECH MR 5000) at a wavelength of 450 nm.
U-937 Colony-Forming Unit (CFU) Assay
The assay was performed as described previously . Colony-forming unit-U937 were cultured in methylcellulose (1%) supplemented with fetal calf serum (FCS, 30%), 1% BSA, 0.1 mM ß-mercaptoethanol, and with or without Tan IIA (2 ug/ml), PXR inhibitor L-sulforaphane (L-SFN) (1 uM) . U937 cells (1 × 103 cells/mL) were seeded in triplicate and incubated for 3 days. The colony was considered as a cluster of 10 or more cells. Colonies were scored blindly.
All experiments were performed in triplicate. The results were expressed as mean ± SD. Correlation analyses were performed using JMP software (version 6, SAS, NC, USA).
Cytotoxicity of Tan IIA on various leukemia cell lines
Specific growth-inhibitory effects of Tan IIA on the U-937 cells
Test of Tan IIA-induced apoptosis in U-937 cells using Annexin V assay
Test of Tan IIA-induced apoptosis in U-937 cells using Caspase 3 assay
Genome-wide expression profiling of U-937 cells treated with Tan IIA
To identify the potential molecular targets of Tan IIA, we employed Affymetrix GeneChip to identify genes that are up- and down-regulated in Tan IIA-treated U-937 cells. After preprocessing the raw data, the ratio of the intensity for each probe from samples treated with Tan IIA to that from untreated samples were calculated. The ratio was further log transformed using base 2 to generate the log2(fold change). All probe sets were then ranked based on the log2 (fold change). Genes that had log2 (fold change) greater than 1 or less than -1 after 12 h or 24 h of Tan IIA treatment were initially selected. These include 366 significantly differentially expressed genes (SDEGs) (Additional file 1, Table S2). From the annotation, many of these genes were found belonging to cell-cycle control, apoptosis pathways. Among the genes related to the apoptosis pathway, chemokine ligand 2 (CCL2, also named monocyte chemoattractant protein-1, MCP-1) is the most significantly down-regulated gene, whose expression has been down-regulated to -3.06- and -3.64-fold in the log scale after 12 and 24 h treatment, respectively. This correspondeded to ~10-fold down-regulation.
To include more genes for apoptosis-related pathways analysis we loosened the selection criteria and the genes that were differentially expressed with absolute fold change > 1.5 were further analyzed. Genes involved in apoptosis, NF-κB cascade and cell proliferation pathways are showed in Additional file 1, Table S3.
Genome-wide expression profiling of five untreated cell lines
To identify genes that are related to U937's sensitivities to Tan IIA, we carried out expression profiling using U133 human GeneChips on five untreated cell lines described in Figure 1. After preprocessing the data, we performed the correlation analyses, in which the correlation between the Tan IIA's toxicity (represented by the percentage of cells that survived after treatment with Tan IIA at 30 μg/mL for 24 h) and the expression levels across the five different cell lines for each probe set was calculated. All probe sets were then sorted based on the correlation coefficient. The correlations for the probe sets significantly differentially expressed after Tan IIA treatment are shown in Additional file 1, Table S4. Compared with the previous experiments, CCL2 has a correlation coefficient of -0.788 and another gene, BCL2A1 has a correlation coefficient of -0.85. It should be pointed out that due to the diverse genetic background of the cell lines, different sets of genes might respond to Tan IIA treatment in these different cell lines. However, we think these results, when combined with those of other experiments, could still provide useful information for genes whose expression level responding to Tan IIA treatment.
Validation of GeneChip data by RT-qPCR analysis
RT-qPCR and ELISA analyses of CCL2 mRNA and protein expression in U-937 cells treated with Tan IIA
Antagonizing Tan IIA activity by PXR inhibitor L-SFN
In the present study, we aimed to systematically investigate the molecular mechanisms underlying the growth inhibitory effect of Tan IIA on leukemia cells. We found that Tan IIA displays significant cytotoxicity on U-937 cells compared with several other cell lines. The inhibitory effects are time- and dose- dependent. The change in cellular morphological features and the results of annexin V/caspase 3 analyses suggest that the induction of apoptosis is responsible for Tan IIA-induced U-937 cell death. Through genome-wide expression profiling, we found that the most significantly regulated gene in response to Tan IIA treatment is chemokine CCL2. These raised two questions: whether or not down-regulation of CCL2 is responsible for cellular apoptosis and how Tan IIA leads to the down-regulation of CCL2.
Chemokines are small heparin-binding proteins that interact with their receptors, regulating many pathophysiological responses in hematological malignancy and inflammatory diseases [21, 22]. CCL2 belongs to the CC chemokine family and is produced by a variety of cell types, including monotype, macrophages and many others. As a potent chemoattractant, CCL2 and its receptor, CCR2, play vital roles in regulating the migration and infiltration of monocyte, T lymphocytes and natural killer cells . Recent studies have described the tumor-promoting roles of CCL2/MCP-1 in eosinophilic leukemia EoL-1 cells  and breast cancel cells [24–27]. Two molecular mechanisms have also been proposed for CCL2's effects. One is that CCL2 negatively regulates AMP-Activated Protein Kinase to sustain mTOR Complex-1 activation, surviving expression and cell survival in human prostate cancer PC3 cells . The other is that CCL2 activates Gi/Go protein/PLC/PKCδ/ p38 MAPK cascade and PKCδ acts as an anti-apoptotic molecule by regulation of the caspase 3 and caspase 9 . Consequently, it is conceivable that the disruption of CCL2 signaling pathways could promote apoptosis and stunt growth of U-937 cells.
During the course of our study, another report showed that Tan IIA is an agonist of pregnane × receptor (PXR, NR1l2) . We then tested the effect of a PXR antagonist, L-SFN on Tan IIA-treated cells using colony forming unit assay and found that L-SFN significantly mitigate Tan IIA's growth-inhibition effect. Previous studies have also showed that nuclear transcription factor-κ B (NF-κB) regulates the transcription of many inflammatory mediators, including CCL2. Lack of NF-κB activity significantly reduced injury-induced CCL2 expression in astrocytes . Sequence analyses have found NF-κB binding sites on the upstream of CCL2 coding sequences . Furthermore, the interaction of PXR and NF-κB has been described . PXR and NF-κB compete for the RXR to form heterodimer which are required for the transcription of their target genes .
In the current study, we showed that Tan IIA, a diterpene quinone extracted from the root of Salvia miltiorrhiza, has significant growth inhibition effect on U-937 cells in vitro through apoptosis induction. Using genome-wide gene expression profiling, we identified hundreds of genes that are significantly up-and down-regulated after Tan IIA treatment. One likely mechanism is that CCL2 is significantly over-expressed in U-937 cells and might play an important role in the survival and proliferation of U-937 cells. Tan IIA activates PXR, which inhibits NF-κB activity, leading to the significantly down-regulation of CCL2 expression by approximately 10-fold, resulting in the apoptosis of U-937 cells.
The authors acknowledge the grant support from HongKong Research Council (HKU7526/06 M, C Liu), startup grant for "Xiehe Scholar" from Chinese Academy of Medical Science (PUMC 2569, C Liu), the Children Cancer Foundation of Hong Kong (M Yang and CK Li), Seed Funding Program of Nanfang Hospital (M Yang), Nanfang Hospital President Foundation (2011A001, M Yang ) and Nanfang Hospital President Foundation (2012C017, FQ Wu).
- Stass SAS, Harold R, Rock , William R: Handbook of hematologic pathology. 2000, New York: Marcel DekkerGoogle Scholar
- Wargovich MJ, Woods C, Hollis DM, Zander ME: Herbals, cancer prevention and health. J Nutr. 2001, 131 (11 Suppl): 3034S-3036S.PubMedGoogle Scholar
- Boon H, Wong J: Botanical medicine and cancer: a review of the safety and efficacy. Expert Opin Pharmacother. 2004, 5 (12): 2485-2501. 10.1517/146565184.108.40.2065.View ArticlePubMedGoogle Scholar
- Sung HJ, Choi SM, Yoon Y, An KS: Tanshinone IIA, an ingredient of Salvia miltiorrhiza BUNGE, induces apoptosis in human leukemia cell lines through the activation of caspase-3. Exp Mol Med. 1999, 31 (4): 174-178.View ArticlePubMedGoogle Scholar
- Liu JJ, Zhang Y, Lin DJ, Xiao RZ: Tanshinone IIA inhibits leukemia THP-1 cell growth by induction of apoptosis. Oncol Rep. 2009, 21 (4): 1075-1081.PubMedGoogle Scholar
- Zhang K, Li J, Meng W, Xing H, Yang Y: C/EBPbeta and CHOP participate in Tanshinone IIA-induced differentiation and apoptosis of acute promyelocytic leukemia cells in vitro. Int J Hematol. 2010, 92 (4): 571-578. 10.1007/s12185-010-0686-6.View ArticlePubMedGoogle Scholar
- Yuan SL, Wei YQ, Wang XJ, Xiao F, Li SF, Zhang J: Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells. World J Gastroenterol. 2004, 10 (14): 2024-2028.View ArticlePubMedPubMed CentralGoogle Scholar
- Su CC, Lin YH: Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios. Int J Mol Med. 2008, 22 (3): 357-361.PubMedGoogle Scholar
- Lu Q, Zhang P, Zhang X, Chen J: Experimental study of the anti-cancer mechanism of tanshinone IIA against human breast cancer. Int J Mol Med. 2009, 24 (6): 773-780.View ArticlePubMedGoogle Scholar
- Zhou L, Chan WK, Xu N, Xiao K, Luo H, Luo KQ, Chang DC: Tanshinone IIA, an isolated compound from Salvia miltiorrhiza Bunge, induces apoptosis in HeLa cells through mitotic arrest. Life Sci. 2008, 83 (11-12): 394-403. 10.1016/j.lfs.2008.07.011.View ArticlePubMedGoogle Scholar
- Pan TL, Hung YC, Wang PW, Chen ST, Hsu TK, Sintupisut N, Cheng CS, Lyu PC: Functional proteomic and structural insights into molecular targets related to the growth inhibitory effect of tanshinone IIA on HeLa cells. Proteomics. 2010, 10 (5): 914-929.PubMedGoogle Scholar
- Chiu TL, Su CC: Tanshinone IIA induces apoptosis in human lung cancer A549 cells through the induction of reactive oxygen species and decreasing the mitochondrial membrane potential. Int J Mol Med. 2010, 25 (2): 231-236.PubMedGoogle Scholar
- van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ, Broekhoven MG, Langenhuijsen MM: A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods. 1994, 174 (1-2): 311-320. 10.1016/0022-1759(94)90034-5.View ArticlePubMedGoogle Scholar
- Liu C, Li J, Meng FY, Liang SX, Deng R, Li CK, Pong NH, Lau CP, Cheng SW, Ye JY: Polysaccharides from the root of Angelica sinensis promotes hematopoiesis and thrombopoiesis through the PI3K/AKT pathway. BMC Complement Altern Med. 2010, 10: 79-10.1186/1472-6882-10-79.View ArticlePubMedPubMed CentralGoogle Scholar
- Li C, Wong WH: DNA-chip analyzer (dChip). 2003, New York: SpringerView ArticleGoogle Scholar
- Li C, Hung Wong W: Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol. 2001, 2 (8): RESEARCH0032-PubMedPubMed CentralGoogle Scholar
- Li C, Wong WH: Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA. 2001, 98 (1): 31-36. 10.1073/pnas.011404098.View ArticlePubMedGoogle Scholar
- Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, Conklin BR: MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol. 2003, 4 (1): R7-10.1186/gb-2003-4-1-r7.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhou C, Poulton EJ, Grun F, Bammler TK, Blumberg B, Thummel KE, Eaton DL: The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol Pharmacol. 2007, 71 (1): 220-229.View ArticlePubMedGoogle Scholar
- Yu C, Ye S, Sun H, Liu Y, Gao L, Shen C, Chen S, Zeng S: PXR-mediated transcriptional activation of CYP3A4 by cryptotanshinone and tanshinone IIA. Chem Biol Interact. 2009, 177 (1): 58-64. 10.1016/j.cbi.2008.08.013.View ArticlePubMedGoogle Scholar
- Broxmeyer HE: Regulation of hematopoiesis by chemokine family members. Int J Hematol. 2001, 74 (1): 9-17. 10.1007/BF02982544.View ArticlePubMedGoogle Scholar
- Murdoch C, Finn A: Chemokine receptors and their role in inflammation and infectious diseases. Blood. 2000, 95 (10): 3032-3043.PubMedGoogle Scholar
- Deshmane SL, Kremlev S, Amini S, Sawaya BE: Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009, 29 (6): 313-326. 10.1089/jir.2008.0027.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee JS, Yang EJ, Kim IS: The roles of MCP-1 and protein kinase C delta activation in human eosinophilic leukemia EoL-1 cells. Cytokine. 2009, 48 (3): 186-195. 10.1016/j.cyto.2009.07.008.View ArticlePubMedGoogle Scholar
- Soria G, Yaal-Hahoshen N, Azenshtein E, Shina S, Leider-Trejo L, Ryvo L, Cohen-Hillel E, Shtabsky A, Ehrlich M, Meshel T: Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine. 2008, 44 (1): 191-200. 10.1016/j.cyto.2008.08.002.View ArticlePubMedGoogle Scholar
- Soria G, Ben-Baruch A: The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2008, 267 (2): 271-285. 10.1016/j.canlet.2008.03.018.View ArticlePubMedGoogle Scholar
- Roca H, Varsos ZS, Pienta KJ: CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells. Neoplasia. 2009, 11 (12): 1309-1317.View ArticlePubMedPubMed CentralGoogle Scholar
- Khorooshi R, Babcock AA, Owens T: NF-kappaB-driven STAT2 and CCL2 expression in astrocytes in response to brain injury. J Immunol. 2008, 181 (10): 7284-7291.View ArticlePubMedGoogle Scholar
- Ueda A, Okuda K, Ohno S, Shirai A, Igarashi T, Matsunaga K, Fukushima J, Kawamoto S, Ishigatsubo Y, Okubo T: NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol. 1994, 153 (5): 2052-2063.PubMedGoogle Scholar
- Zhou C, Tabb MM, Nelson EL, Grun F, Verma S, Sadatrafiei A, Lin M, Mallick S, Forman BM, Thummel KE: Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest. 2006, 116 (8): 2280-2289. 10.1172/JCI26283.View ArticlePubMedPubMed CentralGoogle Scholar
- Gu X, Ke S, Liu D, Sheng T, Thomas PE, Rabson AB, Gallo MA, Xie W, Tian Y: Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem. 2006, 281 (26): 17882-17889. 10.1074/jbc.M601302200.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/12/5/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.